Lawson Kroeker Investment Management Inc. NE Raises Stock Holdings in Elevance Health, Inc. $ELV

Key Points

• Lawson Kroeker Investment Management Inc. NE increased its stake in Elevance Health, Inc. by 2.4%, owning a total of 34,606 shares valued at approximately $13.46 million.
• Recent analyst ratings on Elevance Health show mixed sentiments, with price targets ranging from $297.00 to $440.00, indicating a general consensus of "Moderate Buy."
• CEO Gail Boudreaux acquired 8,500 shares of Elevance Health stock, raising her total holdings to approximately $43.33 million.

Lawson Kroeker Investment Management Inc. NE increased its position in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 2.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,606 shares of the company's stock after purchasing an additional 800 shares during the quarter. Elevance Health accounts for approximately 2.5% of Lawson Kroeker Investment Management Inc. NE's investment portfolio, making the stock its 10th largest position. Lawson Kroeker Investment Management Inc. NE's holdings in Elevance Health were worth $13,460,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Private Wealth Management Group LLC boosted its position in shares of Elevance Health by 152.0% during the 1st quarter. Private Wealth Management Group LLC now owns 63 shares of the company's stock worth $27,000 after acquiring an additional 38 shares in the last quarter. WPG Advisers LLC bought a new stake in Elevance Health during the first quarter worth $29,000. North Capital Inc. acquired a new stake in shares of Elevance Health in the 1st quarter valued at $36,000. Saudi Central Bank bought a new position in shares of Elevance Health in the 1st quarter valued at $40,000. Finally, Berbice Capital Management LLC acquired a new position in shares of Elevance Health during the 1st quarter worth $43,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wall Street Zen lowered Elevance Health from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Truist Financial reduced their price target on shares of Elevance Health from $500.00 to $440.00 and set a "buy" rating on the stock in a research note on Wednesday, July 16th. Robert W. Baird decreased their price target on shares of Elevance Health from $492.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. UBS Group dropped their price objective on shares of Elevance Health from $435.00 to $425.00 and set a "buy" rating for the company in a research note on Friday, September 5th. Finally, Weiss Ratings raised shares of Elevance Health from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, Elevance Health has an average rating of "Moderate Buy" and a consensus price target of $412.00.

Insider Activity

In related news, CEO Gail Boudreaux purchased 8,500 shares of Elevance Health stock in a transaction on Friday, July 18th. The shares were purchased at an average price of $286.94 per share, for a total transaction of $2,438,990.00. Following the transaction, the chief executive officer owned 151,020 shares of the company's stock, valued at approximately $43,333,678.80. This represents a 5.96% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Susan D. Devore purchased 1,200 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was bought at an average cost of $312.15 per share, with a total value of $374,580.00. Following the purchase, the director owned 3,502 shares of the company's stock, valued at approximately $1,093,149.30. This trade represents a 52.13% increase in their position. The disclosure for this purchase can be found here. 0.29% of the stock is currently owned by insiders.

Elevance Health Stock Down 1.4%

NYSE:ELV opened at $353.29 on Friday. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $510.24. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a market cap of $79.55 billion, a PE ratio of 15.03, a P/E/G ratio of 1.29 and a beta of 0.59. The firm's 50 day simple moving average is $315.10 and its 200 day simple moving average is $358.68.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The company reported $8.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.30 by ($0.46). The business had revenue of $49.42 billion during the quarter, compared to analyst estimates of $48.26 billion. Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The company's revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the company posted $10.12 earnings per share. On average, research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 25th. Shareholders of record on Wednesday, September 10th were issued a dividend of $1.71 per share. The ex-dividend date of this dividend was Wednesday, September 10th. This represents a $6.84 annualized dividend and a yield of 1.9%. Elevance Health's payout ratio is presently 29.11%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.